Key statistics
On Friday, Emergent BioSolutions Inc (EBS:NYQ) closed at 10.83, -22.97% below its 52-week high of 14.06, set on Jan 07, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 11.00 |
|---|---|
| High | 11.24 |
| Low | 10.74 |
| Bid | 10.71 |
| Offer | 11.40 |
| Previous close | 10.85 |
| Average volume | 651.84k |
|---|---|
| Shares outstanding | 52.52m |
| Free float | 51.08m |
| P/E (TTM) | 8.38 |
| Market cap | 569.84m USD |
| EPS (TTM) | 1.29 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
- Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
- Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
- Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
- Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
- Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
- Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
- Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
- Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
More ▼
